The changing roles and targets for animal models of schizophrenia

Biological Psychiatry

Volumn 50, Issue 11, 2001, Pages 845-855

  Kilts, Clinton D ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; GLUTAMIC ACID; NEUROLEPTIC AGENT; NEUROTENSIN;

ANIMAL BEHAVIOR; CONFERENCE PAPER; DISEASE COURSE; GENE FREQUENCY; GENETIC MODEL; HERITABILITY; INFORMATION PROCESSING; LATENT INHIBITION; MOLECULAR GENETICS; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; PREPULSE INHIBITION; PRIORITY JOURNAL; PSYCHOPHYSIOLOGY; SCHIZOPHRENIA; SENSORIMOTOR FUNCTION; STIMULUS RESPONSE; SYMPTOMATOLOGY;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DOPAMINE; EVOKED POTENTIALS; GLUTAMIC ACID; HUMANS; MODELS, GENETIC; MODELS, NEUROLOGICAL; NEUROTENSIN; SCHIZOPHRENIA;

EID: 0035667044     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(01)01286-0     Document Type: Conference Paper

References (103)

1. Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects
2. Symptoms, signs, and diagnosis of schizophrenia
3. Impaired auditory gating and P50 nonsuppression following traumatic brain injury
4. Noise stress impairs prefrontal cortical cognitive function in monkeys: Evidence for a hyperdopaminergic mechanism
5. Pharmacology specificity of conditioned avoidance response inhibition in rats: Inhibition by neuroleptics and correlation to dopamine receptor blockage
6. Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical olanzapine
7. Differential performance of acute and chronic schizophrenics in a latent inhibition task
8. Latent inhibition and psychotic proneness in normal subjects
9. Model generation and testing to probe neural circuitry in the cingulate cortex of postmortem schizophrenic brain
10. Enhanced neurotensin neurotransmission is involved in the clinically relevant behavioral effects of antipsychotic drugs: Evidence from animal models of sensorimotor gating
11. On the effect of neonatal nitric oxide synthase inhibition in rats: A potential neurodevelopmental model of schizophrenia
12. Schizophrenia susceptibility loci on chromosomes 13q32 and 8p21
13. Sensorimotor gating and schizophrenia: Human and animal model studies
14. Gating and habituation of the startle reflex in schizophrenic patients
15. Symptom correlates of prepulse inhibition deficits in male schizophrenic patients
16. Location of a major susceptibility locus for familial schizophrenia on chromosome 1q21-q22
17. Inbred mouse strains differ in the regulation of startle and prepulse inhibition of the startle response
18. Abolition and reversal of strain differences in behavioral responses to drugs of abuse after a brief experience
19. Sensory gating deficits assessed by the P50 event-related potential in subjects with schizotypal personality disorder
20. Modulation of the startle response and startle laterality in relatives of schizophrenic patients and in subjects with schizotypal personality disorder: Evidence of inhibitory deficits
21. Latent inhibition-based animal models-implications of effects of phencyclidine and clozapine
22. Sex differences in neuroanatomical and clinical correlations in schizophrenia
23. Genetics of mouse behavior: Interactions with laboratory environment
24. Dopamine in schizophrenia: A review and reconceptualization
25. Comparison of the effects of clozapine, risperidone, and olanzapine on ketamine-induced alterations in regional brain metabolism
26. Prepulse inhibition and latent inhibition: The role of dopamine in the medial prefrontal cortex
27. The behavior of APO-SUS rats in animal models with construct validity for schizophrenia
28. The role of genetic and early environmental factors in determining apomorphine susceptibility
29. The effects of an early stressful life event on sensorimotor gating in adult rats
30. Gene-targeting studies of mammalian behavior: Is it the mutation or the background genotype?
31. Isolation rearing rats produces a deficit in prepulse inhibition of acoustic startle similar to that in schizophrenia
32. The gene encoding proline dehydrogenase modulates sensorimotor gating in mice
33. Dopaminergic mechanisms in the pathogenesis of schizophrenia
34. Latent inhibition in drug naïve schizophrenics: Relationship to duration of illness and dopamine D2 binding using SPECT
35. Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist
36. Latent inhibition effects reflected in event-related brain potentials in healthy controls and schizophrenics
37. An experimental psychological model for schizophrenia
38. Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after chronic PCP
39. The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopaminergic hypothesis of schizophrenia
40. Altered frontal cortical dopaminergic transmission in monkeys after subchronic phencyclidine exposure: Involvement in frontostriatal cognitive deficits
41. Is P50 suppression a measure of sensory gating in schizophrenia?
42. Amphetamine-induced disruptions of latent inhibition are reinforcer mediated: Implications for animal models of schizophrenic attentional dysfunction
43. Differential effects of intra-accumbens and systemic amphetamine on latent inhibition using an on-baseline, within-subject conditioned suppression paradigm
44. Animal behavioral models of schizophrenia
45. Differential effect of antipsychotic drugs on the neurotensin concentration of discrete rate brain nuclei
46. Effects of acute and subchronic administration of typical and atypical antipsychotic drugs on the neurotensin system of the rat brain
47. Rat strain differences in ability to disrupt sensorimotor gating are limited to the dopaminergic system, specific to prepulse inhibition, and unrelated to changes in startle amplitude or nucleus accumbens dopamine receptor sensitivity
48. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses
49. Correlation between antiavoidance activities of antipsychotic drugs in rats and daily clinical doses
50. Ketamine activates psychosis and alters limbic blood flow in schizophrenia
51. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia
52. Lack of effect of an early stressful life event on sensorimotor gating in adult rats
53. Long-term effects of repeated maternal separation on three different latent inhibition paradigms
54. Is there a neuropathology of schizophrenia? Recent findings converge on altered thalamic-prefrontal cortical connectivity
55. Genetic variation in vulnerability to the behavioral effects of neonatal hippocampal damage in rats
56. To model a psychiatric disorder in animals: Schizophrenia as a reality test
57. Assessment of locomotor activity, acoustic and tactile startle, and prepulse inhibition of startle in inbred mouse strains and F1 hybrids: Implications of genetic background for single gene and quantitative trait loci analyses
58. The effects of neuropeptides on discrete-trial conditioned avoidance responding
59. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics
60. NMDA receptor function and human cognition - The effects of ketamine in healthy volunteers
61. Effects of ketamine, MK-801, and amphetamine on regional brain 2-deoxyglucose uptake in freely moving mice
62. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia
63. Neurotensin: Perchance an endogenous neuroleptic?
64. Sensory gating in chronic posttraumatic stress disorder: Reduced auditory P50 suppression in combat veterans
65. Cavum septi pellucidi in normals and patients with schizophrenia as detected by magnetic resonance imaging
66. Psychiatric genetics: Back to the future
67. Schizophrenics show spatial working memory deficits
68. A D2 dopamine receptor agonist disrupts sensorimotor gating in rats. Implications for dopaminergic abnormalities in schizophrenia
69. Chronic treatment with haloperidol diminishes the phencyclidine-induced sensorimotor gating deficit in rats
70. Dopaminergic and glutamatergic blocking drugs differentially regulate glutamic acid decarboxylase mRNA in mouse brain
71. Atypical antipsychotic drugs selectively increase neurotensin efflux in dopamine terminal regions
72. 4, receptor subtype is essential for the disruption of prepulse inhibition produced by amphetamine in mice
73. The catalepsy test: Its ups and downs
74. Inducible gene targeting in mice using the Cre/lox system
75. Support for a chromosome 18p locus conferring susceptibility to functional psychoses in families with schizophrenia, by association and linkage analysis
76. Schizophrenic deficits in the processing of context
77. The latent inhibition model dissociates between clozapine, haloperidol, and ritanserin
78. Catecholamines in the brain as mediators of amphetamine psychosis
79. Disrupted latent inhibition in the rat with chronic amphetamine or haloperidol-induced supersensitivity: Relationship to schizophrenic attention disorder
80. A potential vulnerability locus for schizophrenia on chromosome 6p24-22: Evidence for genetic heterogeneity
81. Seroquel restores sensorimotor gating in phencyclidine-treated rats
82. A preliminary assessment of sensorimotor gating in patient with obsessive compulsive disorder
83. Schizophrenic-like sensorimotor gating abnormalities in rats following dopamine infusion into the nucleus accumbens
84. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients
85. Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia
86. The effects of spiperone, raclopride, SCH 23390 and clozapine on apomorphine-inhibition of sensorimotor gating of the startle response in the rat
87. Increased sensitivity to the sensorimotor gating-disruptive effects of apomorphine after lesion of medial prefrontal cortex or ventral hippocampus in adult rats
88. Toward understanding the biology of a complex phenotype: Rat strain and substrain differences in the sensorimotor gating-disruptive effects of dopamine agonists
89. Gender differences in onset of illness, treatment response, course, and biological indexed in first-episode schizophrenic patients
90. Dissection of behavior and psychiatric disorders using the mouse as a model
91. Distinct functions of the two isoforms of dopamine D2 receptors
92. Differences between three rat strains in sensitivity to prepulse inhibition of an acoustic startle response: Influence of apomorphine and phencyclidine pretreatment
93. Mutagenesis and mapping of a mouse gene, clock, essential for circadian behavior
94. 67 messenger RNA expression in a subset of prefrontal cortical (γ-aminobutyric acid neurons in subjects with schizophrenia)
95. Phencyclidine does not disrupt latent inhibition in rats: Implications for animal models of schizophrenia
96. Abolition of expression but not acquisition of latent inhibition by chronic amphetamine in rats
97. Animal models of depression and schizophrenia
98. Social isolation in the rat produces developmentally specific deficits in prepulse inhibition of the acoustic startle response without disrupting latent inhibition
99. Reduced latent inhibition in people with schizophrenia: An effect of psychosis or of its treatment
100. The validity of animal models of depression
101. A subclass of prefrontal y-aminobutyric acid axon terminals are selectively altered in schizophrenia